Novocure Ltd

NASDAQ NVCR

Data sourced from iex and EODHD
Download Data

Novocure Ltd Working Capital To Sales Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -15.76%

Novocure Ltd Working Capital To Sales Ratio 5 year CAGR is -15.76% for the Trailing 12 Months (TTM) ending March 31, 2024, a -244.82% change year over year. The working capital to sales ratio measures the proportion of working capital to revenue. It is calculated by dividing the difference between current assets and current liabilities by revenue. This ratio provides insights into the efficiency of working capital utilization relative to revenue generation. A higher ratio suggests better utilization of working capital to generate sales revenue. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Novocure Ltd Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 7.32, a 4.71% change year over year.
  • Novocure Ltd Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 6.99, a 50.92% change year over year.
  • Novocure Ltd Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 4.63, a 30.02% change year over year.
  • Novocure Ltd Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 3.56, a -5.78% change year over year.
NASDAQ: NVCR

Novocure Ltd

CEO Mr. William F. Doyle
IPO Date Oct. 2, 2015
Location Jersey
Headquarters No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
Employees 1,453
Sector Healthcare
Industry Medical devices
Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Similar companies

INMD

InMode Ltd

NA

NA

IRTC

iRhythm Technologies Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email